Clinical trial
Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid…
NCT00005604 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00005604 |
|---|---|
| Title | Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors |
| Official title | Phase I Trial of Twice Weekly IV IL-12 Plus Low-Dose Subcutaneous IL-2 in Patients With Advanced Malignancies |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological, Other |
| Interventions | recombinant interleukin-12, aldesleukin, laboratory biomarker analysis |
| Enrollment | 25 |
| Start date | Mar 1, 2000 |
| Primary completion | Jul 1, 2003 |
| First posted | Jul 24, 2003 |
| Last update posted | Feb 1, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: